A5013971145- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood Coagulation and Thrombosis Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood groups and transfusion
- Complement system in diseases
- Cancer-related gene regulation
- Gastrointestinal Bleeding Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- FinTech, Crowdfunding, Digital Finance
- Renal Diseases and Glomerulopathies
- Autoimmune Bullous Skin Diseases
- Blood disorders and treatments
Takeda (United States)
2020-2024
Synta Pharmaceuticals (United States)
2022-2024
Intracranial hemorrhage (ICH), a serious complication in persons with hemophilia A (PWHA), causes high rates of mortality and morbidity. Identified ICH risk factors from patient data spanning 1998-2008 require reassessment light changes the current treatment landscape.
GOAL-Hēm is a novel, haemophilia-specific, patient-centred outcome measure (PCOM) based on goal attainment scaling, allowing people with haemophilia (PwH) to set and monitor the of individualized goals for treatment.To provide thorough overview creation, validation, development GOAL-Hēm.Clinician workshops were held develop haemophilia-specific menu. Qualitative data from semistructured interviews PwH their caregivers guided further revisions menu (i.e., domains descriptors). A feasibility...
This study retrospectively compared annualized billed bleed rates (ABRb) in people with hemophilia A (PwHA) without inhibitors who switched from factor VIII (FVIII) prophylaxis to emicizumab.A real-world comparison was performed on the effect of switching FVIII emicizumab male, non-inhibitor patients ABRb using an all-payer claims database (APCD) dataset 1 January 2014, 31 March 2021. The identification period November 2017, 30 September 2020.One hundred and thirty-one were included a total...
BACKGROUND: Hemophilia A is often viewed as a male disease; females are usually considered asymptomatic hemophilia carriers. However, carriers may experience mild-to-severe bleeding events. OBJECTIVE: To compare clinical characteristics, health care resource utilization, and costs incurred by compared with non–hemophilia carrier female control population in the United States. METHODS: This retrospective observational cohort study used data from IBM MarketScan Commercial Claims Encounters...
Factor VIII (FVIII) replacement and emicizumab have demonstrated efficacy for prevention of bleeds among patients with hemophilia A (PwHA) compared to on-demand (OD) use. Evidence investigating clinical outcomes healthcare costs non-inhibitor PwHA switching from prophylaxis FVIII concentrates has not been well-established within large real-world datasets. This study aimed investigate billed annualized bleed rates (ABRb) total cost care (TCC) FVIII-prophylaxis emicizumab-prophylaxis.This...
BackgroundGoal Attainment Scaling for Hemophilia (GOAL‐Hēm) is a novel, hemophilia‐specific, validated patient engagement tool and patient‐reported outcome instrument.ObjectiveWe evaluated the degree to which language of GOAL‐Hēm was patient‐centric content valuable relevant people with hemophilia (PWH) and/or their caregivers.Patients/MethodsPatients caregivers participated in one three investigations: an online survey, one‐on‐one interviews, or focus group. The survey interviews assessed...
Abstract Introduction Females with haemophilia A (HA [FHAs]) and HA carriers (HACs) have an increased risk of bleeding complications compared to the general population. Aim To examine characteristics, billed annualised bleed rates (ABR b ), costs healthcare resource utilisation for males (MHAs), FHAs HACs in United States. Methods Data were extracted from IBM® MarketScan® Research Databases (Commercial Medicaid) claims during index period (July 2016 September 2018) analysed across MHAs,...
Abstract Introduction In recent years, there has been increased focus on individualizing treatment for persons with hemophilia including pharmacokinetic‐guided (PK) dosing. Aims this retrospective study clinical outcomes before and after PK‐guided prophylaxis were examined. Materials methods Eight Haemophilia Treatment Centres from the United States participated in included 132 patients classified into two cohorts: those undergoing a PK‐assessment product switch (switchers) or to optimize...
Background Von Willebrand disease (VWD) is underdiagnosed, often delaying treatment. VWD claims coding limited, including no severity qualifiers; improved identification methods for are needed. This study's aim: identify and characterize undiagnosed symptomatic persons with in the US using medical insurance to develop predictive machine learning (ML) models.
Background Factor VIII (FVIII) replacement and emicizumab are effective at preventing bleeds in patients with hemophilia A (HA). Though benefits of among inhibitor HA (PwHA) well established, more real-world evidence non-inhibitor is needed.Methods Using a United States healthcare claims database, we compared billed annualized bleed rates (ABRb) the total cost care (TCC) before after switching from FVIII prophylaxis to male PwHA. Bayesian inferences were used assess difference ABRb TCC per...
To describe the economic burden among VWD patients with angiodysplasia compared to without and general population.This was a retrospective analysis using Merative MarketScan Commercial Medicare Databases® (January 2011-September 2020). Selected had ≥1 medical claim for or low VWF, AGD, ≥3 GI-related bleeding episodes within year. HCRU all-cause costs were (only) cohorts.The mean total $150,101 (n = 34), higher $48,249 matched 136) $31,029 individuals of population [n 136; p-value < 0.0001]....